Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665

Leukemia and Lymphoma

Volumn 57, Issue 10, 2016, Pages 2298-2306

  DeBoer, Rebecca ^a   Koval, Gregory ^a   Mulkey, Flora ^b   Wetzler, Meir ^c   Devine, Steven ^d   Marcucci, Guido ^e   Stone, Richard M ^f   Larson, Richard A ^a   Bloomfield, Clara D ^d   Geyer, Susan ^g   Mullighan, Charles G ^h   Stock, Wendy ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g UNIVERSITY OF SOUTH FLORIDA   (United States)

^h ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Drug resistance; lymphoid leukemia; prognostication; transcription factor changes

Indexed keywords

ABL1 KINASE; GENOMIC DNA; IKAROS TRANSCRIPTION FACTOR; IMATINIB; PHOSPHOTRANSFERASE; UNCLASSIFIED DRUG; ABELSON KINASE; BCR ABL PROTEIN; IKZF1 PROTEIN, HUMAN; TUMOR MARKER;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHROMOSOME ABERRATION; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; FEMALE; GENE DELETION; GENE MUTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INDUCTION CHEMOTHERAPY; LEUKEMIA RELAPSE; LEUKOCYTE COUNT; MALE; MINIMAL RESIDUAL DISEASE; MUTATIONAL ANALYSIS; PHILADELPHIA CHROMOSOME POSITIVE CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; CHEMISTRY; DNA MUTATIONAL ANALYSIS; GENETICS; MIDDLE AGED; MORTALITY; MUTATION; PROGNOSIS; PROTEIN DOMAIN; SURVIVAL ANALYSIS; YOUNG ADULT;

ADULT; BIOMARKERS, TUMOR; DNA MUTATIONAL ANALYSIS; FEMALE; FUSION PROTEINS, BCR-ABL; GENE DELETION; HUMANS; IKAROS TRANSCRIPTION FACTOR; LEUKOCYTE COUNT; MALE; MIDDLE AGED; MUTATION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTO-ONCOGENE PROTEINS C-ABL; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84958751941     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2016.1144881     Document Type: Article

References (33)

1. C.Mullighan, C.Miller, I.Radtke,. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature. 2008;453:110–114.
2. C.Virely, S.Moulin, C.Cobaleda,. Haploinsufficiency of the IKZF1 (IKAROS) tumor suppressor gene cooperates with BCR-ABL in a transgenic model of acute lymphoblastic leukemia. Leukemia. 2010;24:1200–1204.
3. H.Schjerven, J.McLaughlin, T.L.Arenzana,. Selective regulation of lymphopoiesis and leukemogenesis by individual zinc fingers of Ikaros. Nat Immunol. 2013;14:1073–1083.
4. G.Martinelli, I.Iacobucci, C.Storlazzi,. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapase:A GIMEMA AL WB report. J Clini Oncol. 2009;27:5202–5207.
5. A.van der Veer, M.Zaliova, F.Mottadelli,. IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL. Blood. 2014;123:1691–1698.
6. H.Pfeifer, K.Raum, S.Markovic,. In adult Philadelphia chromosome positive acute lymphoblastic leukemia, the negative prognostic impact of IKZF1, CDKN2A/B and PAX5 deletions is not abrogated by allogeneic stem cell tranplantation in first complete remission. Blood (Suppl). 2013;122:Abstract 231
7. W.Hofmann, M.Komor, B.Wassmann,. Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph + acute lymphoblastic leukemia. Blood. 2003;102:659–661.
8. H.Pfeifer, B.Wassmann, A.Pavlova,. Kinase domain mutations of BCR-ABL frequently preced imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL). Blood. 2007;110:727–734.
9. D.Jones, D.Thomas, C.Yin,. Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors. Cancer. 2008;113:985–994.
10. S.Soverini, A.Vitale, A.Poerio,. Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis. Haematologica. 2011;96:552–557.
11. H.Pfeifer, T.Lange, S.Wystub,. Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia. Leukemia. 2012;26:1475–1481.
12. M.Wetzler, D.Watson, W.Stock,. Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation:results of a CALGB Study 10001 (Alliance). Haematologica. 2014;99:111–115.
13. W.Stock, D.Yu, T.Karrison,. Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples. Int J Oncol. 2006;28:1099–1103.
14. S.Soverini, G.Martinelli, M.Amabile,. Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib. Clin Chem. 2004;50:1205–1213.
15. F.Gruber, T.Lamark, A.Anonli,. Selecting and deselecting imatinib resistant clones:observations made by longitudinal, quantitative monitoring of mutated BCR-ABL. Leukemia. 2005;19:2159–2165.
16. C.Mullighan, S.Goorha, I.Radtke,. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007;446:758–764.
17. M.Lin, L.Wei, W.Sellers,. dChipSNP:significance curve and clustering of SNP-array-based loss-of-heterozygosity data. Bioinformatics. 2004;20:1233–1240.
18. E.Venkatraman, A.Olshen A faster circular binary segmentation algorithm for the analysis of array CGH data. Bioinformatics. 2007;23:657–663.
19. E.L.Kaplan, P.Meier Nonparametric estimation from incomplete observations. JASA. 1958;53:457–481.
20. D.R.Cox Regression models and life-tables. J R Stat Soc Series B Stat Methodol. 1972;34:187–220.
21. R Core Team. R:A language and environment for statistical computing. R Foundation for statistical Computing, Vienna, Austria. 2014;URL http://www.R-project.org/ [last accessed August 2015].
22. G.Koval, M.Wetzler, D.Watson,. Abl kinase domain mutations leading to relapse of Ph + acute lymphoblastic leukemia (ALL) occur commonly and can be detected at initial diagnosis:molecular results from CALGB 10001. Blood (Suppl). 2011;118:Abstract 2541
23. J.Martinez-Serra, A.Gutierrez, T.F.Marcus,. Four-channel asymmetric Real-Time PCR hybridization probe assay:a rapid pre-screening method for critical BCR-ABL kinase domain mutations. Clin Biochem. 2012;45:345–351.
24. M.Churchman, J.Low, C.Qu,. Efficacy of retinoids in IKZF1-mutated BCR-ABL1 acute lymphoblastic leukemia. Cancer Cell. 2015;28:343–356.
25. I.Iacobucci, C.Storlazzi, D.Cilloni,. Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients:on behalf of Gruppo Italiano Malattie Ematologiche dell' Adulto Acute Leukemia Working Party (GIMEMA AL WP). Lymphoid Neoplasia. 2009;114:2159–2167.
26. S.Chiaretti, A.Vitale, L.Elia,. First results of the multicenter total therapy Gimema LAL 1509 protocol for de novo adult Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) patients. Blood (Suppl). 2014;124:Abstract 797
27. J.P.Radich, H.Dai, M.Mao,. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA. 2006;103:2794–2799.
28. F.Ravandi, S.O’Brien, D.Thomas,. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood. 2010;116:2070–2077.
29. R.Foa, A.Vitale, M.Vignetti,. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2011;118:6521–6528.
30. N.Daver, D.Thomas, F.Ravandi,. Final report of a phase II study if imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica. 2015;100:653–661.
31. E.Jabbour, H.Kantarjian, F.Ravandi,. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia:a single-centre, phase 2 study. Lancet Oncol. 2015;16:1547–1555.
32. T.Burmeister, S.Schwartz, C.R.Bartram,. Patients’ age and BCR-ABL frequency in adult B-precursor ALL:a retrospective analysis from the GMALL study group. Blood. 2008;112:918–919.
33. R.DeBoer, F.Mulkey, G.Koval,. Clinical impact of Abl1 kinase and IKZF1 mutations in adults with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL):molecular analysis of CALGB 10001 and 9665 (Alliance). Haematologica (Suppl 1) 2014;99:Abstract 258.